Venture Capital News: Breaking Venture Capital News, Comments and Articles. - Page: 4

19:05 EST 5th March 2015 | BioPortfolio

Venture Capital News - Page: 4RSS

Read the latest Venture Capital News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Venture Capital.

Search or Follow Our Venture Capital - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Venture Capital - Page: 4 News.

Showing "venture capital" News Articles 76 to 100 of 7,400+

Wednesday 4th March 2015

NASDAQ OMX Riga: CORRECTION: Transactions reported by AS "Olainfarm" insider

Financial and Capital Market Commission Official Obligatory Information Centralized Storage System contains corrected announcement on insider trades with AS "Olainfarm" shares (OLF1R, ISIN code: LV...

Aratana Therapeutics to Present at the Barclays Global Healthcare Conference

KANSAS CITY, Kan., March 4, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that it will present at the Barclays Global Healthcare Conference to be held March 10-12, 2015, at the Loews Miami Beach Hotel in Miami,...

GTSO Opens Talks to Acquire Cannabis Testing and Quality Control Facilities

In its mission to acquire promising laboratory assets in the nation’s top cannabis markets, Green Technology Solutions, Inc. (OTCBB: GTSO) has now opened talks to acquire facil

BRIEF-Selvita establishes new wholly-owned unit in the US

* Establishes new wholly-owned unit Selvita Inc based in the US with capital of $100,000 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated

NEWARK, N.J., March 4, 2015 /PRNewswire/ -- Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contra...

BRIEF-Medical Prognosis Institute says Oncology Venture receives $800,000 ICIP grant

* Says Oncology Venture, MPI's drug development arm and Lantern Pharma receive ICIP grant to advance Irofulven for metastatic prostate cancer

InspireMD Announces Public Offering for Approximately $13.5 Million

BOSTON, March 4, 2015 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced that it has entered into a definitive agreement to sell up to approximately 34 million shares of common stock and warrants to purchase up to approximately 34 million shares of common stock in a public offering.  T...

IMRIS Reports Fourth Quarter and Annual 2014 Financial Results

New order bookings of $4.7 million in fourth quarter resulted in ending backlog of $116.4 million; New order bookings totaled $51.4 million in 2014, up 55.8 percent versus $33 million in 2013; Quarterly revenues of $9.6 million were near IMRIS' expectations, resulting in full-year revenues of $28.9 million; Gross margin reached 41.1 percent in the fourth quarter; Net loss in the fourth quart...

Catasys to Present at the 27th Annual ROTH Capital Growth Conference

LOS ANGELES, March 4, 2015 /PRNewswire/ -- Catasys, Inc. (OTCQB: CATS), provider of proprietary healthcare management services to health insurers and other third party payors, announced today that it has been invited to present at the upcoming 27th Annual ROTH Conference. The conference will be held on March 8-11, 2015 at The Ritz-Carlton Laguna Niguel in Dana Point, California. Event: ROT...

CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer

ROCKVILLE, Md., March 4, 2015 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, is pleased to announce the appointment of Rong Chen MD, Ph.D. as Chief Medical Offi...

VWR Corporation Reports Strong Fourth Quarter and Full Year 2014 Financial Results

RADNOR, Pa., March 4, 2015 /PRNewswire/ -- VWR Corporation (NASDAQ: VWR), a leading, independent provider of laboratory products, services and solutions to the global life sciences, general research and applied markets, today reported its financial results for the fourth quarter and full year ended December 31, 2014. Fourth Quarter 2014 Highlights: Consolidated revenues increased $42.3 mil...

Tuesday 3rd March 2015

Cannabis Investment Firm, Lizada Capital LLC Signs $15M Deal to Become Medbox's Largest Shareholder

LOS ANGELES, March 4, 2015 (GLOBE NEWSWIRE) -- P. Vincent Mehdizadeh, founder and current majority shareholder of Medbox, Inc. (OTCQB:MDBX) announced today that an agreement has been executed with Lizada Capital LLC, an investor in the field of legal cannabis products, that would result in the transfer of the majority of Mr. Mehdizadeh's shares of MDBX to that firm. Under the agreement, Lizada ...

Foundation HealthCare to Present at ROTH Capital Partners 27th Annual Growth Stock Conference

OKLAHOMA CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Foundation HealthCare, Inc. (OTCQB:FDNH), which is an owner and operator of surgical hospitals, today announced that Stanton Nelson, the company's Chief Executive Officer will present at the ROTH Capital Partners 27th Annual Growth Stock Conference to be held at The Ritz Carlton in Dana Point, California, on March 8-11, 2015. Mr. Nelson will be p...

Sirona Biochem: Positive Preclinical Toxicology Results for its SGLT2 Inhibitor Trigger Milestone Payment from Wanbang Biopharmaceuticals

VANCOUVER, BC--(Marketwired - March 04, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed the toxicology study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes. In the study, SBM-TFC-039 was orally administered to Sprague Dawley (SD) rats ...

Oncology Venture, MPI's drug development arm and Lantern Pharma receive ICIP grant to advance Irofulven for metastatic prostate cancer

HORSHOLM, Denmark, March 4, 2015 (GLOBE NEWSWIRE) -- Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, US) announced today that Oncology Venture - the drug development arm of MPI and Lantern Pharma have been awarded an USD 800,000 ICIP grant to support their partnership to clinically advance Irofulven for the treatment of metastatic castration resistant prostrate cancer (mCRPC) b...

LED Medical Diagnostics, Inc. Retains MZ Group as Investor Relations Advisor

ATLANTA, GA--(Marketwired - March 04, 2015) -   LED Medical Diagnostics, Inc. (the "Company" or "LED Medical") (TSX VENTURE: LMD) (OTCQX: LEDIF) (FRANKFURT: LME),  a provider of advanced diagnostic imaging products and software to dentists and oral health specialists, announced it has retained MZ Group as its investor relations advisor.  MZ Group will assist LED Medical with all aspects of c...

OpGen Files Registration Statement for Proposed Initial Public Offering

OpGen, Inc. today announces the filing of its registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to its proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. OpGen is in the process of applying to list its common s...

WI’s Badger Fund of Funds Unlocks State Money, Eyes First Recipients

Nearly two years ago, Wisconsin passed a law creating a government-backed “fund-of-funds” that would invest in venture capital funds in the state, in the hopes of boosting the meager amounts of local cash available to local startups. Now, after m...

RegeneRx, G-treeBNT create JV around ophthalmic candidate RGN259

Teaming up for the second time, RegeneRx Biopharmaceuticals Inc. and G-treeBNT Co. Ltd. (formerly Digital Aria) created a yet-to-be named joint venture that will hold exclusive US rights to the former's Phase II RGN259 for dry eye and the orphan cond...

Series D lands $15.5mm for Daktari

Daktari Diagnostics Inc. (infectious disease tests) raised $15.5mm in its Series D financing led by new backer Eastern Capital and returning investor Merck Global Health Innovation Fund, which were joined by other existing shareholders Norwich Ventur...

Mersana brings in $35mm through Series B-1 round

Mersana Therapeutics Inc. (antibody-drug conjugates (ADCs) for cancer) raised $35mm through its Series B-1 round led by existing backer New Enterprise Associates. New investors Rock Springs Capital and former head of R&D from BMS Elliott Sigal, MD, P...

Johnson & Johnson Innovation Announces New Startup Campus

Johnson & Johnson Innovation this week announced the first 10 companies that will be housed at its new Bay Area startup incubator. The venture capital arm of the New Jersey consumer products giant officially unveiled its JLABS@South San Francisco...

Golub Capital Provides One-Loan Debt Facility To Support The Acquisition Of Apex Foot Health Industries By Orthotic Holdings, A Frazier Healthcare Portfolio Company

CHICAGO, March 3, 2015 /PRNewswire/ -- Golub Capital announced today that as Sole Bookrunner, Sole Lead Arranger and Administrative Agent, it provided a GOLD financing to support the acquisition of Apex Foot Health Industries ("Apex") by Orthotic Holdings ("OHI"), a Frazier Healthcare ("Frazier") portfolio company. GOLD financings are Golub Capital's One-Loan Debt facilities. Headquartered ...

BIO Statement of Support for the Introduction of the STRONG Patents Act of 2015

The following statement on the introduction of the STRONG Patents Act of 2015 by Senator Chris Coons (D-DE) may be attributed to BIO President and CEO Jim Greenwood: “BIO supports balanced reforms to reduce abusive patent practices, while maintaining the strong incentives necessary to sustain our nation’s global leadership in biotechnology inn...

InspireMD Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, March 3, 2015 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase common stock. H.C. Wainwright & Co., LLC, is serving as the sole bookrunner for this of...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks